Stacking Up LQDA Against Its Peers – Is It Still a Buy?
Here is how Liquidia (LQDA) stacks up against its peers in size, valuation, growth and margin.
- LQDA’s operating margin of -715.4% is negative, and lowest among peers; REGN has 27.2%.
- LQDA’s revenue growth of 30.2% in the last 12 months is strong, outpacing VRTX, REGN, ALNY, AMGN but lagging ARGX.
- LQDA gained 87.6% in the past year and trades at a PE of -15.7, outperforming its peers.
As a quick background, Liquidia provides inhaled dry powder treprostinil formulation for pulmonary arterial hypertension treatment.
| LQDA | VRTX | ARGX | REGN | ALNY | AMGN | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 2.2 | 100.8 | 41.1 | 61.9 | 58.2 | 159.5 |
| Revenue ($ Bil) | 0.0 | 11.4 | 2.6 | 14.1 | 2.3 | 34.1 |
| PE Ratio | -15.7 | 27.7 | 38.6 | 13.8 | -215.8 | 26.9 |
| LTM Revenue Growth | 30.2% | 10.5% | 83.2% | 7.5% | 17.2% | 15.6% |
| LTM Operating Margin | -715.4% | -1.7% | 8.3% | 27.2% | -4.9% | 21.8% |
| LTM FCF Margin | -641.6% | 30.6% | – | 21.0% | -3.2% | 32.0% |
| 12M Market Return | 87.6% | -16.8% | 24.6% | -50.5% | 70.9% | -5.9% |
Why does this matter? LQDA just went up 77.7% in a month – peer comparison puts stock performance, valuation, and financials in context – highlighting whether it is truly outperforming, lagging behind, and above all – can this continue? Read Buy or Sell LQDA Stock to see if Liquidia holds up as a quality investment. Furthermore, there is always a risk of fall after a strong rally – see how the stock has dipped and recovered in the past through LQDA Dip Buyer Analysis lens.
While peer comparison is critical Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risks while giving upside exposure.
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| LQDA | 30.2% | -20.0% | 9.7% | 24.0% |
| VRTX | 10.5% | 11.7% | 10.5% | 17.9% |
| ARGX | 83.2% | 78.6% | 198.6% | -17.4% |
| REGN | 7.5% | 8.3% | 7.8% | -24.3% |
| ALNY | 17.2% | 23.0% | 76.2% | 22.9% |
| AMGN | 15.6% | 18.6% | 7.1% | 1.3% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| LQDA | -715.4% | -866.6% | -419.6% | -243.3% |
| VRTX | -1.7% | -2.1% | 38.3% | 47.6% |
| ARGX | 8.3% | -0.8% | -34.3% | -176.2% |
| REGN | 27.2% | 28.1% | 30.9% | 38.9% |
| ALNY | -4.9% | -7.9% | -15.4% | -75.7% |
| AMGN | 21.8% | 21.7% | 28.0% | 36.3% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| LQDA | -7.5 | -7.1 | -10.0 | -9.5 |
| VRTX | 31.4 | -193.9 | 29.0 | 22.3 |
| ARGX | 31.6 | 44.2 | -73.7 | -29.0 |
| REGN | 12.5 | 17.4 | 23.7 | 17.8 |
| ALNY | -156.8 | -108.0 | -54.3 | -25.6 |
| AMGN | 25.3 | 34.2 | 22.9 | 21.6 |
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.